What Kailera Therapeutics does

Kailera Therapeutics is a clinical-stage biotechnology company founded in 2024 and headquartered in Waltham, Massachusetts, developing GLP-1-based injectable and oral therapies for chronic weight management. The company's entire pipeline — four clinical-stage product candidates — was in-licensed from Jiangsu Hengrui Pharmaceuticals in May 2024, with Kailera holding exclusive development and commercialization rights outside of Greater China (China, Hong Kong, Macau, Taiwan). The portfolio includes ribupatide (KAI-9531), a once-weekly injectable GLP-1/GIP receptor dual agonist; an oral tablet formulation of ribupatide; KAI-7535, a once-daily oral small-molecule GLP-1 receptor agonist; and KAI-4729, a once-weekly injectable GLP-1/GIP/glucagon tri-agonist designed for improved liver fat reduction alongside weight loss. Over 2,500 participants have been dosed with ribupatide across Hengrui-conducted trials in China and Kailera-conducted global studies, and Phase 2 data showed 23.6% mean body weight loss at 36 weeks on the 8 mg dose versus 1.7% on placebo.

Kailera's lead program is now in three concurrent global Phase 3 trials (the KaiNETIC-1, -2, and -3 studies) at doses up to 10 mg, with topline results expected in Q1 2028 and a potential US launch targeted for 2029. The company has assembled an unusually experienced commercial-oriented leadership bench for a pre-launch biotech, including a Chief Commercial Officer recruited from Eli Lilly's Zepbound launch team and a CFO with a track record of biotech exits (Dicerna to Novo Nordisk for $3.3B; Jnana to Otsuka for ~$1B). The CEO, Ron Renaud, previously led Cerevel Therapeutics to its acquisition by AbbVie.

Kailera generates no product revenue. The company reported a Q1 2026 net loss of $78.9M, driven primarily by $70.9M of R&D expense, and ended the quarter with $581.9M in cash expected to fund operations into mid-2028. Total capital raised since founding exceeds $1.7B, comprising a $400M Series A (October 2024, Bain Capital Life Sciences-led), a $600M Series B (October 2025, Bain Capital Private Equity-led), and a $718.8M Nasdaq IPO in April 2026 that priced at $16/share, opened at $26, and was at the time the largest biotech IPO in history. Future revenue, when it begins, will come from prescription pharmaceutical sales of approved obesity therapies through traditional specialty pharmacy and pharmacy distribution channels; pricing has not yet been disclosed.

Name

Kailera Therapeutics

Legal name

KAILERA Therapeutics

Website

https://kailera.com

Company type

Public

Founded year

2024

Operating status

Operating

Headcount range

101–250 employees

Short description

Kailera Therapeutics is a clinical-stage biotechnology company developing injectable and oral GLP-1-based therapies for chronic weight management, with a lead candidate (ribupatide) in global Phase 3 trials and a targeted 2029 US launch.

Ownership category

akta.pro rank

Product category

Obesity Therapeutics

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Therapeutic Peptides & Protein/Peptide Biologics (HLAAAAAH)

akta.pro secondary industry

Regulatory Strategy & IND/NDA/BLA Submissions Support (HLAIALAH)

Keywords

• Obesity therapeutics
• GLP-1 receptor agonists
• Metabolic disease drugs
• Peptide drug development
• Clinical-stage biopharmaceutical

Headquarters

HQ city

Waltham

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Pharmaceutical Product Sales: Kailera is a clinical-stage biotech with no marketed products. The company plans to commercialize its obesity drug pipeline, with lead candidate ribupatide potentially launching in the US by 2029. Revenue will come from product sales of prescription obesity treatments.

Go-to-market motion1 record

Marketing channels4 records

Core offering

Kailera Therapeutics is a clinical-stage biotechnology company developing a diversified pipeline of GLP-1-based injectable and oral therapies for chronic weight management in adults with obesity and overweight conditions. Its lead product candidate ribupatide (KAI-9531) is a once-weekly injectable GLP-1/GIP receptor dual agonist in global Phase 3 development, supported by an oral ribupatide tablet, an oral small molecule GLP-1 agonist (KAI-7535), and an injectable GLP-1/GIP/glucagon tri-agonist (KAI-4729). All candidates were in-licensed from Jiangsu Hengrui Pharmaceuticals, with Kailera holding exclusive development and commercialization rights outside of Greater China.

Product overview

Kailera Therapeutics is a clinical-stage biotechnology company developing a diversified pipeline of four clinical-stage GLP-1-based product candidates for obesity treatment. The company's portfolio includes ribupatide (KAI-9531), a once-weekly injectable GLP-1/GIP receptor dual agonist currently in global Phase 3 trials; an oral tablet formulation of ribupatide; KAI-7535, an oral small molecule GLP-1 receptor agonist; and KAI-4729, a once-weekly injectable triple agonist. All product candidates were in-licensed from Jiangsu Hengrui Pharmaceuticals, with Kailera holding exclusive rights outside China, Hong Kong, Macau, and Taiwan. The company has no marketed products and is focused exclusively on advancing clinical development through Phase 3 trials.

Differentiator

Problem solved

Functional benefit

Products and services

• Ribupatide (KAI-9531) A once-weekly injectable GLP-1/GIP receptor dual agonist peptide in clinical development for the treatment of obesity and overweight conditions, currently in global Phase 3 trials (KaiNETIC-1, KaiNETIC-2, KaiNETIC-3). Over 2,500 clinical trial participants have been dosed across multiple late-stage trials in China and global studies, with 23.6% mean body weight loss demonstrated in Phase 2 trials at the 8mg dose at 36 weeks. Designed with modified potency on GLP-1 and GIP receptors and longer half-life than leading obesity medications, providing improved exposure through the full weekly dosing period.
• Oral Ribupatide A once-daily oral tablet formulation of ribupatide (GLP-1/GIP receptor dual agonist) in clinical development for obesity treatment, with potential for compelling weight loss and highly differentiated tolerability among oral obesity medicines. Up to 12.1% mean weight loss was demonstrated at 26 weeks in Phase 2. Designed to address patient preference for non-injectable therapies and the market gap for oral GLP-1 obesity treatments with compelling efficacy.
• KAI-7535 A once-daily oral small molecule GLP-1 receptor agonist in clinical development for the treatment of obesity, with potential to offer competitive weight loss and tolerability profile compared to other oral GLP-1 therapies. Leverages small-molecule chemistry rather than peptide technology, distinguishing it from injectable and oral peptide competitors in the pipeline.
• KAI-4729 A once-weekly injectable GLP-1/GIP/glucagon receptor tri-agonist in clinical development for obesity treatment, with potential for compelling weight loss, improved liver fat reduction, and a differentiated tolerability profile. The glucagon receptor addition enables liver fat reduction benefit beyond what dual agonists provide. Designed to address severe obesity cases and patients with metabolic comorbidities.

Quantifiable outcome

• 23.6% mean body weight loss at 36 weeks (Phase 2, 8mg dose) vs 1.7% for placebo
• +4 more outcomes

Segments2 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• Jiangsu Hengrui Pharmaceuticals (Hengrui)coreStrategic or Co-development Partner · 1 May 2024Strategic collaboration for obesity drug development. Kailera holds exclusive rights to development and commercialization of product candidates outside of China, Hong Kong, Macau, and Taiwan. Hengrui retains Greater China rights and conducts clinical trials in China that provide data informing Kailera's global development plans. Kailera in-licensed four GLP-1 obesity assets including ribupatide (KAI-9531/HRS9531), KAI-7535, and KAI-4729.

Scale indicators8 records

Recent moves8 records

Expansion highlights6 records

Emerging players

• Zealand Pharma: Develops survodutide (a GLP-1/glucagon dual agonist) in partnership with Boehringer Ingelheim. Comparable mechanism to KAI-4729 and overlapping obesity clinical-stage profile.
• Terns Pharmaceuticals: Clinical-stage company with oral obesity candidates including TERN-601 (oral GLP-1). Competes with Kailera's oral ribupatide and KAI-7535 in the oral GLP-1 segment.
• Metsera: Emerging clinical-stage obesity biotech developing oral and injectable peptide therapies. Represents a newer entrant in the same clinical-stage obesity category as Kailera, often referenced as a peer comparator.

Direct peers

• Viking Therapeutics: Clinical-stage biotech developing VK2735 (injectable and oral GLP-1/GIP dual agonist) for obesity, with a directly comparable mechanism and clinical-stage profile. One of the most frequently cited direct comparables to ribupatide.
• Structure Therapeutics: Clinical-stage company developing GSBR-1290, an oral GLP-1 receptor agonist for obesity. Direct competitor in the oral GLP-1 segment where Kailera's oral ribupatide and KAI-7535 also compete.
• Altimmune: Clinical-stage biotech developing pemvidutide, a GLP-1/glucagon dual agonist for obesity. Comparable to Kailera's KAI-4729 triple-agonist strategy and competing in late-stage obesity trials.

Broad incumbents

• Eli Lilly: Develops and markets Zepbound (tirzepatide) for obesity and Mounjaro, the current GLP-1/GIP dual-agonist market leader that ribupatide is designed to compete against. Kailera's ex-Zepbound brand leader (Jamie Coleman) now leads Kailera's commercial build-out.
• Roche: Advancing CT-388 (GLP-1/GIP dual agonist) and CT-996 (oral GLP-1) acquired via the Carmot deal. Large incumbent with R&D and commercial resources to compete in obesity across injectable and oral modalities.
• Novo Nordisk: Sells Wegovy (semaglutide) and Ozempic, the foundational GLP-1 obesity and diabetes franchises. The dominant incumbent in the GLP-1 category and the primary competitive reference point for any new obesity entrant.

Regional players

• Innovent Biologics: China-based biotech developing mazdutide (a GLP-1/glucagon dual agonist) in partnership with Eli Lilly. Holds China rights analogous to Hengrui's position versus Kailera and represents a regional competitor in the same mechanism class.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xx.com/kaileratx
• LinkedInlinkedin.com/company/kaileratx

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds2 records

Investors15 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Kailera Therapeutics